The t(8;21) is associated with 12 ± 15% of acute myelogenous leukemias of the M2 subtype. The translocation results in the fusion of two genes, AML1 (CBFA2) on chromosome 21 and ETO (MTG8) on chromosome 8. AML1 encodes a DNA binding factor; the ETO protein product is less well characterized, but is thought to be a transcription factor. Here we describe the isolation and characterization of ETO-2, a murine cDNA that encodes a new member of the ETO family of proteins. ETO-2 is 75% identical to murine ETO and shares very high sequence identities over four regions of the protein with ETO (domain I ± III and zinc-®nger). Northern analysis identi®es ETO-2 transcripts in many of the murine tissues analysed and in the developing mouse embryo. ETO-2 is also expressed in myeloid and erythroid cell lines. We con®rmed the nuclear localization of ETO-2 and demonstrated that domain III and the zinc-®nger region are not required for nuclear localization. We further showed that a region within ETO, containing domain II, mediates dimerization among family members. This region is conserved in the oncoprotein AML-1/ETO. The recent identi®cation of another ETO-like protein, myeloid translocation generelated protein 1, together with the data presented here, demonstrates that at least three ETO proteins exist with the potential to form dimers in the cell nucleus.
The t(8;21) is associated with 12 ± 15% of acute myelogenous leukemias of the M2 subtype. The translocation results in the fusion of two genes, AML1 (CBFA2) on chromosome 21 and ETO (MTG8) on chromosome 8. AML1 encodes a DNA binding factor; the ETO protein product is less well characterized, but is thought to be a transcription factor. Here we describe the isolation and characterization of ETO-2, a murine cDNA that encodes a new member of the ETO family of proteins. ETO-2 is 75% identical to murine ETO and shares very high sequence identities over four regions of the protein with ETO (domain I ± III and zinc-®nger). Northern analysis identi®es ETO-2 transcripts in many of the murine tissues analysed and in the developing mouse embryo. ETO-2 is also expressed in myeloid and erythroid cell lines. We con®rmed the nuclear localization of ETO-2 and demonstrated that domain III and the zinc-®nger region are not required for nuclear localization. We further showed that a region within ETO, containing domain II, mediates dimerization among family members. This region is conserved in the oncoprotein AML-1/ETO. The recent identi®cation of another ETO-like protein, myeloid translocation generelated protein 1, together with the data presented here, demonstrates that at least three ETO proteins exist with the potential to form dimers in the cell nucleus.
Keywords: ETO family; MTG8; (8;21) translocation; nuclear; dimerization Of the many chromosomal translocations associated with acute myelogenous leukemia (AML), the t(8;21) is one of the most common, accounting for approximately 15% of the M2 subtype (Rowley, 1984) . This translocation results in the fusion of the AML1 (CBFA2) gene on chromosome 21 and the ETO (MTG8) gene on chromosome 8. The resultant hybrid gene-product, AML-1/ETO, is comprised of the ®rst 177 amino acids of AML-1 and includes all but the ®rst 30 amino acids of the ETO (MTG8b) protein (Erickson et al., 1992; Kozu et al., 1993; Miyoshi et al., 1993) . AML-1/ETO, expressed from the AML1 promoter, is thought to be central to leukemogenesis as its reciprocal chimeric mRNA and protein have not been observed.
AML1 encodes several alternatively spliced transcription factors; AML-1 (250 aa), AML-1b (453 aa), Figure 1 ETO-2 is a new member of the ETO-family of proteins. (a) The amino acid sequence of murine ETO-2 (mETO-2). The regions of highest conservation among family members were de®ned by using the multiple sequence alignment program Pileup and are underlined. The asterisks (*) denote every tenth amino acid. The sequence data reported here has been deposited in the GenBank sequence databases under the accession number AFO38029. A mouse spleen cDNA library constructed in the Lambda Zap II bacteriophage vector was plated and screened according to the manufacturer's directions (Stratagene). The DNA sequence of both strands of the cDNA was determined by primer walking using dideoxy-chain termination and double stranded DNA template (Iowa State University Sequencing Facility). The full-length cDNA sequence was analysed using Wisconsin GCG software installed on a VAX computer. (b) Schematic representation of the relationship between four of the ETO-family members. The ETO-family proteins are shown as linear molecules with nervy on top for comparison. The four regions of greatest conservation among family members are shown enclosed in the boxes and are designated as domain I, II, III and zinc-®nger. The numbers within the domains on the linear molecule denote the Nand C-terminal amino acid boundaries of each of the domains for each protein. Percent identities and similarities between nervy and murine ETO (mETO) are shown for each domain. The percent identity of mETO and MTGR1 to ETO-2 are given for each domain. Human ETO is not shown but is 99% identical overall to murine ETO. While this manuscript was under review, the description of a third ETO-related protein from humans was published and was termed MTG16 (Gamou et al., 1998) . ETO-2 is more closely related to MTG16 than to the other ETO proteins and may represent the murine homologue of MTG16 and AML-1B (480 aa) (Miyoshi et al., 1991; Bae et al., 1994; Levanon et al., 1994; . AML-1B contains a C-terminal transactivation domain and a nuclear matrix targeting signal not found in AML-1 (Bae et al., 1994; Zeng et al., 1997) . The AML-1 proteins and the related AML-2 and AML-3 proteins are the human counterparts of the DNA binding components of the murine transcription factor complex core binding factor (CBF), also called polyoma enhancer binding protein (PEBP2) (Ogawa et al., 1993; Wang and Speck, 1992; Bae et al., 1994; Speck and Terryl, 1995) . The AML-1 DNA binding domain is known as the runt homology domain (rhd) because of its similarity to sequences in the Drosophila segmentation protein runt (Kania et al., 1990; Meyers et al., 1993) . The rhd also mediates interaction with core binding factor b(CBFb) . AML-1B is expressed in hematopoietic tissue and regulates the transcription of a variety of genes involved in hematopoiesis through its DNA binding site, the`core motif ' (TGT/CGGT) (Melnia b
Characterization of ETO-2 JN Davis et al kova et al., 1993; Meyers et al., 1993 Zhang et al., 1996) . AML-1/ETO retains the rhd Miyoshi et al., 1993) . Moreover, AML-1/ETO inhibits AML-1B-mediated transactivation of the TCell Receptor b (TCRb) gene enhancer and the granulocyte-macrophage-colony stimulating factor (GM-CSF) promoter (Frank et al., 1995; . The very small amounts of AML-1/ETO required for these eects suggest dominant inhibition. Therefore, one possible outcome of the expression of AML-1/ETO in t(8;21)-containing cells would be the dominant inhibition of AML-1B function.
Although the role of the AML-1 proteins as DNA binding factors is well characterized, the biological function of ETO has yet to be de®ned. The Drosophila homologue of ETO, nervy, is expressed in the developing¯y nervous system and is thought to mediate a segment-speci®c identity function of the homeotic genes in the central nervous system (Feinstein et al., 1995) . In mice, ETO is highly expressed in brain, testis and ovary and, to a lesser extent, in lung and heart . In the brain, ETO expression is high in newborn mice, but appears to decline in older mice, which suggests a role in nervous system development (Erickson et al., 1994) . Of interest, ETO mRNA has been detected in the human hematopoietic cell lines HEL (erythroleukemia) and Raji (Burkitt's lymphoma) . Additionally, a recent report detected ETO protein in CD34+ cells from human bone marrow, suggesting a role for ETO in human hematopoiesis (Erickson et al., 1996) .
A comparison of the ETO and nervy proteins reveals three regions of striking homology: nervy residues + RNA extracted from whole mouse embryos on the days as indicated post-conceptus. The Northern blot was sequentially hybridized to ETO-2, ETO and b-actin probes as indicated. Arrows indicate the message, and the molecular weights are shown. Exposure times are 16 h for ETO-2 and ETO, 2 h for b-actin. The mouse tissue and whole embryo Northern blots were purchased (Clontech) and were hybridized and washed according to supplier's instructions. (c) poly (A) + RNA was isolated for Northern analysis by using the PolyATtract mRNA isolation system IV (Promega) from the following cell lines: L-cells (ATCC CCL-1); B104 (rat neuronal); NRK (kidney; ATCC CRL-6509), F9 (embryonal carcinoma; ATCC CRL-1720); MEF; 32D; FDC-P1 (myeloid, v-fms transformed) (Wheeler et al., 1987) ; WEHI-3 (Lee et al., 1982) ; MEL (erythroid leukemia); NSF112 (Askew et al., 1993) ; and EL-4 (lymphoma; ATCC TIB-39). Approximately 2 mg of poly (A) + RNA was fractionated on a 2.2 M formaldehyde ± 1.5% agarose gel and immobilized on nylon by capillary transfer. The Northern blot was hybridized sequentially to an ETO-2, ETO and a b-actin probe. The position of the message is marked with an arrow and labeled; the molecular weights are given. Exposure times were 24 and 72 h for ETO-2 and ETO, respectively, and 2 h for b-actin Myc epitope is N-terminal to the ETO-2 and ETO proteins and is shown stippled and labeled as myc-tag. The results of the localization experiment performed in part B is given in the schematic and is indicated as N (nuclear) or C (cytoplasmic). The ETO-2 cDNA, representing residues 1 ± 620, was prepared by PCR and cloned into the XbaI site of the eukaryotic expression vector pJ3M (Sells and Cherno, 1995) . This vector contains a well characterized 10 amino acid peptide (MEQKLISEEDL) from the Myc protein N-terminal to the multiple cloning linker recognized by the monoclonal antibody 9E10 (Evan et al., 1985) . pJ3METO-2 (1 ± 412) was prepared using an internal BamHI site and is cloned into pJ3M at the XbaI and BamHI sites. pJ3METO-2 (1 ± 273) was prepared by PCR using the following primers; TATCTAGAATGTCCCAGGCATCCACCACC and TAGGATCCTCACCTGT-CAGGTGTTCTCCT. The resultant PCR product was sequenced. pJ3METO (431 ± 604) was made by using an endogenous EcoRI site in the human ETO (MTG8b) sequence and contains domain III and the zinc-®nger region. (b) The human kidney cell line 293T was transiently transfected with the vector constructs shown in (a) or vector alone using a modi®cation of the calcium phosphate precipitation method (Chen and Okayama, 1987) . 24 ± 48 h later, the cells were washed with 2 ml of 16PBS and then ®xed in ethanol/acetone (1 : 1) for 20 min at 7208C. The cells were then blocked in 10% normal goat serum (Sigma) before being probed 211 ± 308, 454 ± 480 and 519 ± 632 (Feinstein et al., 1995) . Residues 211 ± 308 contain part of an overlapping region with homology to the TATA binding protein-associated factor TAF110 (Hoey et al., 1993) . This region of similarity also partially overlaps with the Sp1 and CREB interaction domains, which suggests that ETO-family proteins may interact with transcription factors (Hoey et al., 1993) . Nervy residues 519 ± 632 contain two potential zinc-®ngers that are highly conserved between the human and Drosophila proteins. It is unclear whether the zinc-®nger region of ETO mediates DNA binding or protein interactions (Kozu et al., 1997) . The smallest of the regions (residues 454 ± 480) is leucine-rich, and the comparable region in ETO can be modeled as an amphipathic alpha helix .
As part of our eort to understand the role of ETO in t(8;21)-containing leukemia, we asked whether ETO homologues existed in hematopoietic cells. We reasoned that if ETO-like proteins are expressed in such cells, the functions of these proteins might be subverted by dysregulated ETO expression as a result of the 8;21 translocation. In this study, we have isolated and characterized ETO-2, encoding a third member of the ETO protein family in vertebrates, from a murine spleen cDNA library. The isolated cDNA extends for 2691 nucleotides and contains an open reading frame that encodes a protein highly homologous to ETO. The molecular mass of the predicted protein encoded by the ETO-2 cDNA is approximately 71 kD. At the 3' end of the cDNA is an oligo (dA) stretch that likely represents the poly(A) + tail of the mRNA. The major open reading frame of the cDNA remains open up to the 5' end, which makes it dicult to de®ne the true initiating methionine. However, the mRNA derived from the cDNA is eciently translated in vitro and in vivo, and the sequence contains all of the regions known to be conserved among ETO family members, which gives us con®dence that we have the entire open reading frame.
The predicted protein product of the ETO-2 cDNA is shown, and the regions of greatest conservation among family members are underlined (Figure 1a ). ETO-2 shares 75% identity with murine ETO (mETO) and 77% identity with human ETO. ETO-2 and nervy share 32% identity. While this manuscript was in preparation, Kitabayashi et al. published the description of a human ETO-related protein, termed MTGR1, that shares 60% identity with ETO-2. Because ETO-2 is more closely related to murine and human ETO than to MTGR1, we believe that ETO-2 is not the murine homologue of MTGR1 but a third member of the ETO-family found in vertebrates.
Our comparison of the amino acid sequence of ETO-2 with murine ETO and MTGR1 revealed four highly conserved domains designated domain I, II, III and zinc-®nger (Figure 1b) . These four domains relate to the three regions of highest conservation originally described between nervy and ETO; the original third region of conservation can now be seen to actually consist of two separate conserved domains, III and the zinc-®nger region. Domain I, contained within ETO-2 residues 146 ± 242, has previously been shown to have limited homology to a Drosophilia transcription accessory factor, TAF110 (Feinstein et al., 1995) . This TAF-related domain is common to several TAFs isolated from vertebrates, including hTAFII 135, hTAFII 130 and the related hTAFII 105 (Tanese et al., 1996; Dickstein et al., 1996) . Domain II (ETO-2 residues 371 ± 402) is a leucine-rich region that apparently mediates homo-and heterodimerization between the ETO family of proteins ( Figure 5) . A functional role for domain III (ETO-2 residues 461 ± 510) has not been identi®ed. The zinc-®nger domain is very highly conserved among family members and is contained in ETO-2 amino acids 533 ± 572. This zinc®nger region shares homology with those of the rat, mouse, and C. elegans RP-8 protein, identi®ed as a gene induced upon programmed cell death; the BOP protein (for CD8b opposite) expressed in several long term CTL lines and in the thymus; and in the Drosophila transcription factor DEAF1, where it is thought to mediate protein interactions (Owens et al., 1991; Gross and McGinnis, 1996; Hwang and Gottlieb, 1997) .
The expression pattern of ETO-2 was examined by Northern blot analysis of poly(A) + RNA isolated from various adult mouse tissues, rodent cell lines and whole mouse embryos. Two ETO-2 messages of approximately 4.4 and 8.0 kb are present in most adult mouse tissues analysed, including spleen (Figure 2a ). ETO-2 expression was very strong in heart, brain, spleen and lung and appeared to be lowest in liver and testis. In testis, the 8.0 kb message could not be detected, but a 6.0 kb message, together with the 4.4 kb transcript, could be seen after a long exposure (50 h; data not shown). This contrasts somewhat with the expression of ETO in the same tissue. ETO message was detected in the murine brain, heart, lung and testis but not in the spleen, liver, muscle or kidney (Figure 2a ). This is in agreement with previous reports of ETO expression in brain, heart, testis, and ovary .
with the mouse monoclonal antibody 9E10 (diluted 1 : 50 in 16PBS+0.2% Triton X-100). A Cy3-conjugated goat anti-mouse antibody (diluted 1 : 200) was used to detect 9E10 binding (seen as red/orange). The cells were then washed twice in 16PBS+0.2% triton X-100 and then were stained with a FITC-conjugated anti-pan cytokeratin monoclonal antibody, clone C-11 (diluted 1 : 200 and seen as green) (Sigma). The representative samples shown are: panel A, pJ3M vector transfected only; panel B and C, pJ3METO-2; panel D, pJ3METO-2 (1 ± 412) and panel E, pJ3METO-2 (1 ± 273) panel F, pJ3MhETO (431 ± 604). The red (Cy-3) and green (FITC)¯uorescent signals were visualized using an Olympus BX-60 epi¯uorescence microscope equipped with appropriate single-and dual-pass ®lters speci®c for FITC and Cy-3¯uorescence and digital image processing (Chroma Technologies). Monochrome images were captured at the microscope using a cooled-CCD camera and pseudocolored composite images were produced using software speci®cally designed for multi-color image analysis. Arrows indicate the cells that are expressing the epitope-tagged ETO-2 and ETO constructs. (c) Expression of the epitope-tagged ETO-2 and ETO proteins in 293T cells. 293T cells transfected with the pJ3METO-2 and ETO vectors were harvested and whole cell extracts made from these cells were separated on 10% SDS ± PAGE. The proteins were transferred to a nitrocellulose membrane and were detected with the 9E10 antibody (diluted 1 : 800 in the presence of 1% dry milk) and a goat anti-mouse IgG(H+L)-alkaline phosphatase conjugated secondary antibody (Bio-Rad Laboratories) and the Immun-Star detection kit (Bio-Rad laboratories). The ®lter was exposed to Kodac ®lm for 2 m. The positions of the molecular weight standards (apparent) are shown Because the ETO message is expressed to high levels in the brain of newborn mice and declines as the mice age (Erickson et al., 1994) , we looked for both ETO and ETO-2 expression in whole mouse embryos. The mRNAs for both ETO and ETO-2 were present at day 7 post conceptus, and levels for both messages had dramatically increased by day 11. These levels were maintained up to day 17 (Figure 2b) . Thus, both ETO-2 and ETO are expressed during murine embryogenesis.
Poly(A) + RNA from eleven rodent cell lines, including T-cell, B-cell, and myeloid lineage lines, were analysed for ETO-2 expression. The 4.4 kb ETO-2 message is present in the myeloid cell line FDCP-1 as well as the erythroid cell line MEL ( Figure   2c ). The 8.0 kb message was not detectable on this exposure but can be seen after a longer exposure time (data not shown). Neither ETO-2 message was detectable in the other cell lines analysed even after a prolonged exposure time. For comparison, we analysed the same cell lines for ETO expression. Only the teratocarcinoma cell line F9 showed ETO expression (Figure 2c) . ETO may be a transcription factor given its limited homology to TAF 110, and its localization to the nucleus (Erickson et al., 1996; Kozu et al., 1997) . To con®rm and extend this idea to ETO-2, we prepared epitope-tagged versions of wild-type and mutant ETO-2 proteins for use in cellular localization studies. We chose the epitope commonly called the`myc tag', recognized by the monoclonal antibody 9E10. A schematic representation of the proteins used for these studies is shown in Figure 3a . The pJ3METO-2 (1 ± 412) construct produced a protein that lacks the entire zinc-®nger region and domain III. The pJ3METO-2 (1 ± 273) construct produced a protein that lacks all of domain II, domain III and the zinc-®nger region. The pJ3MhETO (432 ± 604) protein product is comprised of domain III and the zinc-®nger region of human ETO (MTG8b). Wild-type ETO-2, mutant ETO-2, and the ETO (432 ± 604) constructs were transfected into the human cell line 293T and analysed for their subcellular localization. A Cy3-conjugated goat anti-mouse antibody was used to detect 9E10 antibody binding (red/ orange). The cells were also reacted with a FITCconjugated pan-cytokeratin antibody to delineate the small cytoplasmic region in these cells (green) (Fuchs and Cleveland, 1998) . The cellular localization of ETO-2, ETO-2 (1 ± 412), ETO-2 (1 ± 273), and ETO (432 ± 604) proteins is shown in Figure 4b . ETO-2 and ETO-2 (1 ± 412) can easily be seen in the cell nucleus (panels B, C, and D). Domain III and the zinc-®nger region, which are absent from ETO-2 (1 ± 412), are not required for this localization. ETO-2 (1 ± 273) is cytoplasmic (panel E). For comparison, epitope tagged hETO (432 ± 604) was analysed. In this case, the protein can be seen clearly in the cytoplasm of the cell (panel F). Control cells transfected with vector alone are shown in panel A. Parallel transfection and Western analysis using the 9E10 monoclonal antibody Figure 4 A region containing domain II is sucient to direct in vitro interactions among ETO family members. (a) Schematic representation of the four glutathione-S-transferase (GST) ± ETO proteins used in dimerization studies. The GST moiety is Nterminal, and labeled. The conserved domains are shaded; conserved domains I ± III and the zinc ®nger region are labeled I, II, III, and ZF, respectively. The proteins are labeled to indicate which ETO amino acids are fused to the GST molecule. GST ± ETO 1 ± 604 is a recombinant protein containing all 604 amino acids of the human ETO (MTG8b) protein subcloned into pGEX4T-1 (Pharmacia) at the XHOI site. ETO segments representing amino acids 108 ± 248 and 335 ± 392 were made by PCR using the following primers: TAGGATCCATGTCTCTGGCTAATCAACAG plus TAGAATTCGCCTGGGGTTCTGTCTGG and TAGGATCCACACGTCAAGAAGAAATG plus TAGAATTCCCAGTAATTCAATTCTTC, respectively. The resultant PCR fragments were sequenced and then cloned into pGEX 2T for protein production. The pGEX ZF construct was made by using an internal BamHI site in the native ETO (MTG8b) sequence and represents amino acids 393 ± 604. (b) In vitro interaction of ETO with itself. GST ± ETO 1-604 or GST proteins were produced in E. coli and puri®ed on GST-agarose beads. The bead-linked proteins, as labeled above the lanes, were incubated with in vitro produced 35 S-methionine-labeled ETO protein for 1 h. The beads were pelleted, washed four times in immunoprecipitation buer (IP) [50 mM Tris-Cl (pH 7.5) 150 mM NaCl, 0.4% NP-40, 1 mM EDTA, 0.1% bovine serum albumin (BSA)] and once in IP buer without BSA and resuspended in 30 ml of gel loading buer before being separated on 10% SDS ± PAGE. One ml of the programmed rabbit reticulocyte lysate was run for comparison and is labeled hETO inv T/T. The arrow indicates the ETO protein. The proteins were visualized with Coomassie-blue and the gels were dried and subject to autoradiography. Below panel B is shown the Coomassie-blue stained GST and GST ± ETO proteins as labeled and indicated with arrows. The asterisk (*) denotes residual BSA. (c) In vitro GST-capture assay. GST ± ETO 108 ± 248, GST ± ETO 335 ± 392 and GST ± ETO 393 ± 604 were prepared in E. coli and puri®ed on GST-agarose beads. The bead-linked proteins, as labeled above the lanes, were incubated with in vitro produced 35 S-methionine-labeled ETO protein for 1 h and then treated exactly as stated in part B. Rabbit reticulocyte lysate (1 ml) was run for comparison and is labeled hETO inv T/T. Below panel C, the coomassie-blue stained GST ± ETO proteins used in the experiment are shown. The asterisk (*) denotes BSA. (d) Rabbit reticulocyte lysates (10 ml), programmed with the AML-1/ETO cDNA and 35 S-methionine, were mixed with GST ± ETO 108 ± 248, GST ± ETO 335 ± 392 and GST ± ETO 393 ± 604 bound to glutathione beads. Samples were then treated as stated in (b) 1 ml of the labeled lysate was run for comparison and is labeled AML-1/ETO inv T/T. The arrow indicates the full length AML-1/ETO protein. (e) Rabbit reticulocyte lysates (10 ml), programmed with the mouse ETO-2 cDNA and [ 35 S]-methionine, were mixed with GST ± ETO 108 ± 248, GST ± ETO 335 ± 392 and GST ± ETO 393 ± 604 bound to glutathione beads. Samples were then treated as stated in (b) 1 ml of the labeled lysate was run for comparison and is labeled ETO-2 inv T/T. The arrow indicates the ETO-2 protein. In all cases the exposure times shown are 12 ± 16 h. The apparent molecular weights are given for each panel. For production of in vitro transcribed/ translated proteins, rabbit reticulocyte lysates were programmed with the human ETO (MTG8b), ETO-2 or AML-1/ETO cDNA in pBluescript (Stratagene) and [ 35 S]methionine (ICN) by using the TNT system according to manufacture's instructions (Promega) con®rmed that the constructs used in the localization studies were expressed (Figure 3c ).
We previously demonstrated that a region encompassing domain II is required for AML-1/ETO's ability to inhibit AML-1B-mediated transactivation of the TCR b gene enhancer . Domain II is a leucine-rich region that can be modeled as an amphipathic alpha helix, reminiscent of proteininteraction motifs . To assess whether ETO homodimerizes, we constructed glutathione-S-transferase fusion proteins with full length human ETO (GST ± ETO) or the conserved domains and used these proteins in a series of`GSTpull down assays'. A schematic representation of these proteins is shown in Figure 4a . The bacterially expressed GST ± ETO protein was puri®ed on glutathione sepharose and incubated with 35 S-methioninelabeled ETO that had been prepared from rabbit reticulocyte lysates. GST ± ETO, but not GST alone, eciently bound labeled ETO protein, as shown in Figure 3b . The Coomassie-stained GST and GST ± ETO proteins are shown below the pull down assay in panel B. When we prepared GST ± ETO proteins encompassing domain I (GST ± ETO 108 ± 248), domain II (GST ± ETO 335 ± 392) and domain III plus the zinc ®nger region (GST ± ETO 393 ± 604) and repeated the`GST-pull down' experiment with 35 Smethionine labeled ETO, AML-1/ETO, and ETO-2, we found that GST ± ETO 335 ± 392, but not the other ETO segments, eciently bound labeled proteins (Figure 4c , d and e respectively; the Coomassie-stained proteins for Figure 4c are shown below the pull down assay). Therefore, the protein sequences between amino acids 335 ± 392 of human ETO are sucient to mediate dimerization within this group of proteins.
To better understand the function of AML-1/ETO in leukemia, we have begun to investigate the normal cellular role of ETO. As an extension of this eort, we looked for expression of ETO-like proteins in hematopoietic tissue. We have isolated a novel murine cDNA that encodes a protein highly related to the protooncoprotein ETO. Northern analysis demonstrated ETO-2 expression in all murine tissues analysed, which suggests that ETO-2 has a wider expression pattern in adult mouse tissues than does ETO. In cell lines, however, ETO-2 expression appeared limited to myeloid and erythroid lineages. This ®nding was unexpected given ETO-2's apparent ubiquitous tissue expression. We also analysed both ETO and ETO-2 expression in the developing mouse embryo. Our data demonstrate that both genes are highly expressed during murine embryogenesis. Although our analysis does not delineate the speci®c organs that express ETO and ETO-2, it does suggest an important role for both proteins in embryogenesis. We have analysed the co-expression pattern of ETO and ETO-2 and ®nd that they are expressed together in a limited subset of mouse tissues; they were not coexpressed in any of the cell lines we analysed. For this reason, we believe that these two closely related proteins may perform similar functions in a tissuespeci®c manner.
The AML1 (CBFA2) gene is targeted in both the t(8;21) and t(12;21), which results in the creation of the oncoproteins AML-1/ETO (AML-1/MTG8) and TEL/ AML-1, respectively Golub et al., 1995) . Both AML-1/ETO and TEL/AML-1 inhibit AML-1B-mediated transactivation of the TCR b gene enhancer and have been hypothesized to function as strong dominant negative molecules Hiebert et al., 1996) . The ability of AML-1/ETO to inhibit AML-1B-mediated transactivation requires an intact rhd and de®ned regions within ETO .
Deletion mutagenesis has demonstrated that Cterminal truncation of AML-1/ETO to amino acid 469 ablates its dominant inhibitory eects on AML-1B-dependent transactivation, whereas an AML-1/ETO protein that is truncated at amino acid 540 still functions as an inhibitory molecule. Thus, amino acid 469 de®nes the C-terminal boundary of sequences that are required for dominant inhibition . Of interest, the region of AML-1/ETO between residues 469 and 540 includes domain II. Our results demonstrate that a region of 58 amino acids encompassing domain II is sucient to mediate dimerization among ETO-family members in vitro. These data are in agreement with a recently published study that describes the cloning of another ETO-like protein, MTGR1. In this study, AML-1/ETO is shown to interact with MTGR1, and this interaction was lost in C-terminally truncated AML-1/ETO proteins when a region encompassing domain II was removed. Interestingly, the TEL helix ± loop ± helix domain, which is fused to AML-1B in the oncoprotein TEL/ AML-1 and is required for its repression activities, can also mediate dimerization (Hiebert et al., 1996; Jousset et al., 1997) . Thus, AML-1/ETO and TEL/AML-1 contain a protein interaction motif outside of the rhd that may be a key element for their activity.
The sequence of the ETO-family of proteins identi®es multiple modular domains conserved between family members and other transcription factors. The ETO-family putative zinc-®nger region consists of a GATA-like C-C-C-C ®nger and an unusual C-C-H-C ®nger (Kozu et al., 1997) . Zinc®nger domains have been implicated not only in DNA binding but also in protein-protein interactions (Mackay and Crossley, 1998) . This study describes the identi®cation of a novel dimerization motif, which we have mapped to a 58 amino acid region that can potentially be ascribed to domain II. The biological role of the ETO-family of proteins may be to mediate interactions between DNA binding proteins and other transcriptional regulators through these multiple and varied interaction domains.
